Published on
February 28, 2024
- 16:01 GMT
Medera’s Sardocor Granted FDA Orphan Drug Designation for DMD-associated cardiomyopathy Gene Therapy
BOSTON, MA, UNITED STATES, February 28, 2024 /EINPresswire.com/ -- Sardocor Corp., the clinical-stage gene therapy subsidiary of Medera Inc., with a broad pipeline of adeno-associated virus (AAV)-based treatments for cardiovascular diseases, announced that it has been granted Orphan Drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the company’s experimental gene therapy treatment for cardiomyopathy secondary to Duchenne muscular dystrophy (DMD). With an Investigational New …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
